Rosiglitazone therapy

PreclinicalSmall molecule

Rosiglitazone therapy is one of 9 small molecule programs targeting Dilated Cardiomyopathy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dilated CardiomyopathyActive, not recruiting

Dilated CardiomyopathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Dilated Cardiomyopathy

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Approved

—2

Rapamune

PPrism Pharmaceuticals

Approved

1 3

Lotensin

VValidus Pharmaceuticals

Approved

1 4

Atacand

AstraZeneca

Phase 3

1 5

Danicamtiv

Bristol-Myers Squibb

Phase 3

3 6

Avandia

Natrecor

1 8

Other

AstraZeneca

Preclinical

1 9

Rosiglitazone therapy

SStanford University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dilated Cardiomyopathy1 trial

Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy

Terminated·SStanford University·N/A·NCT00466713

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Rosiglitazone therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rosiglitazone therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rosiglitazone therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SStanford University

Rosiglitazone therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dilated Cardiomyopathy1 trial

References

Drug Info

Quick Facts

Related News